Recently, the signing and unveiling ceremony of Medtronic's Digital Health Innovation Center was held at the International Pharmaceutical Innovation Park (BioPark) located in Yizhuang New Town, Beijing.

It is reported that this base is Medtronic's first digital medical innovation base established in China.

According to reports, Medtronic's Digital Health Innovation Center is dedicated to developing disease management solutions based on artificial intelligence and big data. It will focus on building medical training centers in areas such as cardiovascular, minimally invasive surgery, and neuroscience. Additionally, a patient care center will be established, incorporating digital technology to enhance the level of patient prevention management services. A Medtronic Museum will also be built. This innovation center is set to officially begin operations by the end of this year.

Medtronic's first digital medical innovation base established in China.

The base is located in the International Pharmaceutical Innovation Park (BioPark) in the western part of Beijing Yizhuang New City. It is adjacent to the South Central Axis on the west, with the South Fifth Ring Road and Jing-Tai Expressway running through the area, as well as Metro Line 8. Covering an area of 5.8 square kilometers, it is an important industrial functional area in the comprehensive supporting service area of Yizhuang New City and the southern part of the capital.

Not only have all six major centers of the National Medical Products Administration been established here, but it has also attracted several multinational companies, including Medtronic, Eli Lilly, Pfizer, Bayer, Huya Biotechnology, and AstraZeneca. Most of these companies' new research and development or innovation institutions are the "first in Beijing" or "first in China." For example, Bayer will establish an open innovation center; Eli Lilly will set up a China Medical Innovation Center in Beijing’s Yizhuang; Pfizer will establish its first physical R&D center in Beijing; Huya Biotechnology will set up its China headquarters, becoming Beijing's first international platform focused on innovative drugs going abroad. According to the plan, this year, the investment in the International Medical Innovation Park will reach 10 billion yuan.

International Medical Innovation Park BioPark.

BioPark will be planned and constructed as a global collaborative hub for pharmaceutical and health innovation, an internationally influential gathering place for biopharmaceutical industry innovation, the first stop for global pharmaceutical innovation talent to start businesses in China, as well as a national demonstration zone for AI empowerment applications in the pharmaceutical and health industry, and a "testing ground" for the implementation of innovative pharmaceutical policy reforms nationwide.

"After 36 years of deep cultivation in China, Medtronic has always been driven by innovation and resonates with the country's healthcare development. The establishment of the digital healthcare innovation base in Beijing marks a new stage in our comprehensive value chain layout in China. We hope to leverage Beijing’s leading medical resources and innovation momentum, working with partners to create a patient-centric digital healthcare innovation model. Solutions such as remote management and intelligent follow-up will help alleviate the burden on hospitals, improve service efficiency, and enhance the management experience for patients with chronic diseases, contributing to China's development of an intelligent and inclusive healthcare system," said Jeff Martha, Medtronic's Global Chairman and CEO.

It is noteworthy that senior executives from Medtronic have recently participated in several major events and leadership meetings in China.

He Lifeng meets with heads of multinational companies.

On March 23, He Lifeng, a member of the Political Bureau of the Central Committee of the Communist Party of China and Vice Premier of the State Council, met with leaders of well-known multinational companies such as Medtronic, Apple, Pfizer, and Eli Lilly to exchange views on the global and Chinese economic situation, China-U.S. economic and trade cooperation, and expanding investment in China.

He Lifeng stated that China's economy is resilient, has great potential, and is full of vitality. China is steadfast in promoting high-quality development, expanding high-level opening-up, and continuously optimizing the business environment. We welcome multinational companies to increase their investment in China and share development opportunities.

The heads of multinational companies have expressed their attention to the Chinese market, optimism about China's economic prospects, and a willingness to commit to long-term cooperation with China.

China Development Forum Annual Conference 2025

From March 23 to 24, the China Development Forum 2025 Annual Conference was held in Beijing, with the theme "Fully Unleashing Development Potential and Promoting Stable Global Economic Growth." It attracted political leaders from various countries and many heads of multinational companies to attend the conference in China.

During the annual meeting, Medtronic Chairman and CEO Jeff Martha stated that Medtronic firmly believes that China will become the world's largest medical market and an important source of innovation, as well as a strategic hub for medical innovation, investment, and collaboration. Medtronic looks forward to partnering with more industry collaborators to jointly promote the development of new productive forces, advance medical innovation, and improve patient outcomes.

Jeff Martha stated, "In 2025, Medtronic will enter its 36th year of development in China. Considering China's population structure, the growing healthcare needs, and the overall trend of economic development, the potential of the healthcare market in China is undoubtedly enormous."

Visiting Chengdu

On March 25, Cao Lijun, a member of the Standing Committee of the Sichuan Provincial Party Committee and Secretary of the Chengdu Municipal Committee, met with Jeff Martha, the global chairman and CEO of Medtronic, and his delegation.

Cao Lijun welcomed Jeff Massa and his team to Chengdu for inspection, exchange, and cooperation promotion, and briefly introduced the economic and social development situation in Chengdu. He stated that Chengdu is a hub city for international exchanges and one of the most vibrant and happiest cities in China. Currently, Chengdu is comprehensively building a demonstration area for park cities that practice the new development concept, aiming to create a socialist modern international metropolis with global influence and reputation. As a global leader in medical technology, Medtronic has maintained a good cooperative relationship with Chengdu for a long time. He hopes that the company will continue to increase its investment in Chengdu, bringing more quality products, technologies, and services to China and Chengdu, strengthening exchanges and cooperation with Chengdu, and achieving win-win development. We will adhere to the principle of "responding to needs and not disturbing without cause," regularly carry out the work of "entering ten thousand enterprises, solving problems, optimizing the environment, and promoting development," continuously create a first-class business environment that is market-oriented, law-based, and internationalized, and do our utmost to create favorable conditions and provide quality services for enterprise development.

Jeff Massa stated that Chengdu has advantages in industry, talent, technology, and market, with vibrant economic development, and he is very optimistic about Chengdu's future. He will increase investment and cooperation in Chengdu, expand the layout of the industrial and value chains, actively integrate into the local innovation ecosystem, promote the application of new products and technologies in the city, and contribute to the high-quality development of Chengdu's pharmaceutical and health industry, thereby making a greater contribution to enhancing the health and well-being of citizens.

In recent years, Medtronic has continuously increased its investment in China, establishing a local full-value chain layout. Key areas of focus include:

The Lingang Medical Technology Industrial Base is a heart disease management base that integrates high-end medical technology research and localized production, dedicated to providing solutions for heart diseases that meet local needs in the Chinese market. Last year, the base's first product was launched.

Kanghui Changzhou Science and Technology Park is a comprehensive orthopedic and neurosurgery innovation technology park that integrates production, research and development, incubation, and customer experience. The completion of this technology park will have a profound impact on the medical technology industry in the Yangtze River Delta region. Currently, the building has completed its topping-out, and the new building of the technology park is expected to be put into use in 2026.

Changzhou Kandi Production Base: The Medtronic Kandi Integrated Surgical Base project plans to introduce cutting-edge products and technologies from the global surgical field, creating a "smart manufacturing" base and innovation center that integrates high-end surgical product and equipment manufacturing with innovative research and development incubation. This is an important layout for Medtronic in the field of surgical operations. The project was officially signed on October 18th last year.

The Beijing Yizhuang Digital Innovation Service Base, where the signing and unveiling event is held, is an important attempt by Medtronic in the field of digital healthcare. It is evident that Medtronic is expanding its presence in various fields and regions in China.

On February 18, 2025, Medtronic announced its financial performance for the third quarter (Q3) of fiscal year 2025, reporting revenue of approximately $8.3 billion (about 61.09 billion RMB), with a reported growth of 2.5% and an organic growth of 4.1%. This marks the ninth consecutive quarter of mid-single-digit organic revenue growth. Looking ahead, with ongoing investments, can China further enhance its impact on Medtronic's performance? Medical Device Home will continue to monitor this situation.